The Latest Breaking News from Eli Lilly

Eli Lilly has filed three new separate lawsuits accusing vendors and a medical spa of selling knock-off versions of their drug, Zepbound.

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes, obesity, and eczema markets, is it a must-have in your healthcare portfolio? Read on to…

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to taxpayers

Alzheimer’ patients in UK left behind over regulator’s decision to reject use of new drugs

The healthcare market shows promise due to heightened demand for quality care, technological advancements, preventive measures, and increased public investment, ensuring resilience in any economic condition. Therefore, investors could now consider top healthcare stocks, such as Eli Lilly (LLY), Merck & Co. (MRK), and Abbott Laboratories (ABT). Keep reading.

'Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff Sonnenfeld and Steven Tian.

In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease.

The weight loss jab Mounjaro will soon be made available to nearly a quarter of a million NHS patients, according to proposals made by the National Institute for Health and Care Excellence (Nice). Previously, it was only available on the NHS for patients with diabetes.

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term growth. Investors looking to capitalize on this trend might consider adding healthcare giants like Eli Lilly and Company (LLY), UnitedHealth Group (UNH), and Merck & Co. (MRK) to their watchlist. Read…

With a robust performance, strategic expansions, and strong analyst endorsements, Eli Lilly appears poised for continued growth, making it a compelling investment opportunity.